In prostate cancer, systemic administration of a truncated recombinant form (GLIPR1-ΔTM) has demonstrated potent anti-tumor effects, including induction of ROS-mediated apoptosis and suppression of oncogenic c-Myc signaling. The gene discussed is GLIPR1; the disease is neoplasm.